With an FDA review ongoing, Kennedy’s admission, made during a Senate hearing on the Health and Human Services Department’s budget request, suggests political officials could supersede scientific decisions.
HHS Secretary Robert F. Kennedy Jr. answers questions during a Senate HELP Committee hearing on his department's budget request. (Screenshot of Senate HELP Committee Broadcast)
Key Takeaways
HHS Secretary Robert F. Kennedy Jr. said during a Senate hearing on his department’s budget request that a final decision on changes to mifepristone policy would be made by the White House and President Trump.
Health and Human Services Secretary Robert F. Kennedy Jr. suggested that changes to mifepristone labeling may be needed, but conceded...
